Recombinant human tissue inhibitors of metalloproteinases (rhTIMP-2) have been shown to suppress tumor growth and tumor-associated angiogenesis. NCI Radiation Oncology Branch (ROB) researchers have developed a unique HEK-293F cell line which stably expresses rhTIMP-2, increasing the production of TIMP-2 to quantities sufficient to be used for testing and development as a therapeutic for various cancers, ischemic diseases (myocardial infarct and cerebrovascular infarct), and neurodegenerative diseases.
Researchers at the National Cancer Institute (NCI) developed a novel mouse for the detection of TGF-ß signaling. This mouse provides the opportunity to study TGF-ß signaling in vivo and may be a useful model for preclinical pharmacology studies. The NCI seeks licensees for the TGF-ß reporter mouse.
The National Eye Institute (NEI) seeks research co-development or licensees for making research- or clinical-grade preservation solutions for cold-sensitive organ transplantation or protection of brain injury or trauma during surgery.